14 Patanjali Products Suspended by Uttarakhand Government

14 Patanjali Products Suspended – In a big setback for Baba Ramdev’s famous Patanjali Ayurveda company, the Uttarakhand government has suspended the manufacturing licenses of 14 Patanjali Products Suspended. This strict action was taken because Patanjali repeatedly violated advertising laws related to making misleading claims about their products.

14 Patanjali Products Suspended:

1. Swasari Gold – A gold-colored medicine

2. Swasari Vati – Pill/tablet medicine 

3. Bronchom – Medicine for breathing/lungs

4. Swasari Pravahi – Liquid medicine

5. Swasari Avaleh – Soft, chewable medicine

6. MuktaVati Extra Power – Powerful pill/tablet medicine

7. Lipidom – Medicine for cholesterol/fats 

8. Bp Grit – Medicine for blood pressure

9. Madhugrit – Medicine made with honey

10. MadhunashiniVati Extra Power – Powerful anti-diabetes pill/tablet

11. Livamrit Advance – Advanced liver medicine

12. Livogrit – Medicine for liver

13. Eyegrit Gold – Gold-colored eye medicine 

14. Patanjali Drishti Eye Drop – Eye drops

The state licensing authority said in an affidavit that the manufacturing licenses were cancelled due to “repeated violations” of the Drugs and Magic Remedies (Objectionable Advertisements) Act of 1954, which controls how drugs can be advertised.

Legal Battle Ongoing

This suspension comes as Patanjali and its founders are already involved in ongoing legal cases related to misleading advertisements. Earlier, authorities in Haridwar had filed a criminal complaint against Swami Ramdev, Acharya Balkrishna, and the companies Divya Pharmacy and Patanjali Ayurved Limited for violating advertising rules.

The Supreme Court of India is currently hearing a case about Patanjali’s misleading ads. The court had ordered Patanjali to publish an apology in newspapers, but postponed punishment for Ramdev and Balkrishna as they could not file details of the published apology on time.

Also Read | Heatwave Scorches Unexpected Parts of India

Protecting Consumers – 14 Patanjali Products Suspended

This action by the Uttarakhand government shows increasing scrutiny on misleading advertising claims, especially for healthcare products. It highlights the need for honesty in marketing to protect consumers from being misled by exaggerated or false claims about products.

As the legal battle continues, this crackdown sends a clear message that companies must follow advertising rules and ethical marketing practices. Protecting consumers and maintaining public trust in the healthcare industry is very important.

National Correspondent(Smiriti Ramana)

Our prolific Staff Writer at India Observers is committed to delivering a diverse range of news, offering insights across various categories. With a dedication to accurate reporting, the Staff Writer ensures that readers receive timely and comprehensive updates on a myriad of topics. Explore the world of news through the lens of our versatile Staff Writer, bringing you the latest from every corner of the news spectrum.

Recent Posts

Jaishankar Rules Out Bilateral Talks with Pakistan at SCO Summit

External Affairs Minister of India, S Jaishankar is set to visit Pakistan in mid-October to…

October 5, 2024

Dubai Hosts Thrilling South Africa-West Indies Clash in T20 World Cup

ICC Women’s T20 World Cup 2024 kicked off in Dubai with an exciting face-off between…

October 4, 2024

Kick 2 Is Happening! Sajid Nadiadwala Drops First Look of Salman Khan’s Iconic Return

Salman Khan fans have something big to celebrate! Producer Sajid Nadiadwala has officially announced the…

October 4, 2024

Power Outage in Chennai on October 4: Is Your Area on the List?

Chennai will have a power cut on October 4, 2024, as reported by various news…

October 4, 2024

Google Enhances Search Engine with AI-Powered Video and Image Search

As part of the next phase in developing the company’s artificial intelligence, Google is to…

October 4, 2024

OpenAI Secures $6.6 Billion in Funding to Boost AI Research

According to the news sources like Reuters, OpenAI has successfully raised $6.6 billion in new…

October 3, 2024

This website uses cookies.

Read More